However, the lack of EEG epileptogenic activity and the concurrently reduced cortical A2AR immunoreactivity emphasize the potential safety of AGO concerning epileptogenesis as previously reported in a mouse model of epilepsy (Dastgheib & Moezi 2014) and patients (Jiang et al. 2024). This evidence concerns the gene ADORA2A and epilepsy.